Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ROFFUFUFUFUFUFULLL!!!
Startup companies can go years without profits, financials and good business, this is the nature of the beast.
You don't like the fact that the research we've been conducting at Moffitt, is directly tied to Merck? We have patents that are valuable to Merck? What is Orndansetron? How does it equate into the upcoming partnership with M2gen?
YES...there will be a partnership.
The technology is irrefutable.
Please refute any post I've made ragarding the 10k. TIA
!!!THURSDDAY!!!! excellent.eom
Sam, do you know what ondansetron is? Taxol, paclitaxel,... Do you know how it coincides with Merck and their need for personalized medicine? moron.....
liz, if being a distraction ever; paid...everbody would be rich!!
Sam, is that the Golden Patent? Maybe...
Combinations Thereof Predictive of PCT/US02/38345
Paclitaxel Responsiveness in Cancer Patients
Compositions and Methods for Inferring US10/644,594
Ancestry PCT/US03/26229
http://209.85.165.104/search?q=cache:23SwnEumHWsJ:sec.edgar-online.com/2005/01/03/0001144204-04-0232...
sam, all nonsense aside:
Ondansetron has a pronociceptive effect in P-glycoprotein inhibition
2006 OCT 23 -- According to a study from the United States, ondansetron has a pronociceptive effect in P-glycoprotein inhibition.
"Ondansetron is a potent antiemetic drug that acts through inhibition of the 5HT3 receptors for serotonin. Minimum alveolar concentration (MAC) for isoflurane is not affected by systemic ondansetron; however ondansetron is a substrate of P-glycoprotein, a transport pump expressed in the blood-brain barrier. Thus, we hypothesized that central nervous system concentrations of ondansetron might be reduced by the P-gp protein," wrote J.A. Scott and colleagues of Columbia University.
http://www.newsrx.com/article.php?articleID=368412
Conclusions. Our findings suggest that about 54% of a paclitaxel oral dose is extruded to the gut lumen by P-glycoprotein. [b/Thus, the bioavailability of paclitaxel could be enhanced by coadministration of a P-glycoprotein inhibitor, KR-30031.
http://www.springerlink.com/content/m5671g1452510877/
Individual genetic differences have long been suspected to play a role in this variable drug response and this is particularly true for the current standard of care for ovarian cancer – Paclitaxel (Taxol) / Carboplatin (manufactured by Bristol-Myers Squibb).
http://209.85.165.104/search?q=cache:c-1xxh4krekJ:www.dnaprint.com/welcome/productsandservices/pharm...
Combinations Thereof Predictive of PCT/US02/38345
Paclitaxel Responsiveness in Cancer Patients
Compositions and Methods for Inferring US10/644,594
Ancestry PCT/US03/26229
http://209.85.165.104/search?q=cache:23SwnEumHWsJ:sec.edgar-online.com/2005/01/03/0001144204-04-0232...
IMPORTANT CONSIDERATIONS
ZOCOR is a prescription tablet and isn’t right for everyone, including women who are nursing or pregnant or who may become pregnant, and anyone with liver problems. Unexplained muscle pain or weakness could be a sign of a rare but serious side effect and should be reported to your doctor right away. ZOCOR may interact with other medicines or certain foods, increasing your risk of getting this serious side effect. So tell your doctor about any other medications you are taking.
ZOCOR is a registered trademark of Merck & Co., Inc.
http://www.zocor.com/simvastatin/zocor/consumer/product_information/ppi/index.jsp
This is the culmination of a project that was begun when the company was founded," stated DNAPrint President and Chief Executive Officer Richard Gabriel. "It has taken until now to validate the original findings, but validated they are. The Company has filed a patent to protect this process. We plan to bring to market a definitive test product to identify this genetic variant and to potentially prevent painful -- and in some cases, fatal -- side effects in thousands of patients who are taking a very common prescription drug."
DNAPrint's study of 750 patients who had taken either atorvastatin (Lipitor(R)) or simvastatin (Zocor(R)) showed that patients carrying one specific genetic marker were approximately 2.5 times more likely to experience mild to severe muscle pain (myalgia). The effect was most pronounced for atorvastatin and the study showed that approximately one half of the patients who were removed from atorvastatin therapy due to muscle symptoms possess this genetic marker, whereas in the general population (with and without cardiovascular disease) only approximately 15%-25% of people carry the marker. DNAPrint applied its technology for measuring population structure (e.g., ancestry) in order to prove that the finding in both the discovery and validation samples was genuine, and in so doing received praise from JPG reviewers. This observation indicates that the genetic marker may be related not only to response to statins but also to a possible relationship with higher cholesterol levels, according to the study.
"DNA Print Genomics was founded on the underlying genomic screening methods developed to more efficiently scan the genome for medically important genetic markers of drug responses," stated Dr. Frudakis. "The current findings are another example of the efficiency of the Company's methods."
http://www.genengnews.com/news/bnitem.aspx?name=10502612&taxid=27
EMEND (aprepitant) Helps Prevent Nausea/Vomiting for Breast Cancer Patients
the regimen including EMEND (day 1: EMEND 125 mg one hour before chemotherapy, ondansetron 8 mg 30-60 minutes before chemotherapy
EMEND is a registered trademark of Merck & Co
http://www.medicalnewstoday.com/medicalnews.php?newsid=23074
Ondansetron
Through collaboration with the Moffitt Cancer Research Center in Tampa, FL, we are investigating the genetic basis of Ondansetron response. Ondansetron is an anti-emetic for the alleviation of post-operative nausea and vomiting (PONV), but normal doses of the drug do not elicit the desired effect in some patients. A genetic test for predicting Ondansetron response could help reduce extreme discomfort many patients feel after surgery.
March 29, 2004 DNAPrint™ genomics, Inc. Forms Joint Research Program with the H. Lee Moffitt Cancer Center and Research Institute
Now...sam.. Could you please grant your assessment of the company's 10k filing. TIA
sam, what are your opinions of the financial situation of the company now that the 10k has been filed? TIA
I've held for 7 years. And I found out yesterday that we're in dire financial circumstances. Worse that I thought. I feel like Gov. Tarken in Star Wars..."WHAT!...abandon the DEATH STAR in our moment of TRIUMPH!!"
Is everything in black and white just nonsense? Is there going to be a huge deal tomorrow? We'll see. I'm thinking...if they don't get other funding by May (original Dutchess deal expires) it will just get ugly. JMHO
Sam, and here I thought you might appreciate some facts from the 10k. You're right....to da' moon.
Here's what the Athena boy's get:
Investment Banking Agent Agreements
Effective February 1, 2006, we engaged Athena Capital Partners, Inc. (“Athena”) to assist us in our long-term financial planning efforts, including our efforts to raise debt and/or private equity capital. This agreement expires on January 31, 2008. Pursuant to the agreement, we have granted Athena authorization to act as our agent (on a best efforts basis) in the following investment banking activities: private placement of securities, merger and acquisition assistance, debt financing and other services. As consideration for such services, we have agreed to compensate Athena as follows:
Upon closing of a private placement transaction a fee of 10% for the first $5 million, 8% of the next $5 million, 7% of the next $5 million, 6% of the next $5 million and 5% on any amounts that exceed $20 million.
·
Upon closing a debt financing, a transaction fee of 5% of the first $2 million, 3% of the next $3 million and 2.5% of the next $15 million and 2% of any amounts that exceed $20 million.
·
Upon closing a mergers and acquisition transaction, a transaction fee of $5% of the first $10 million, 4% of the next $10 million and 3% of the next $30 million and 2% of any amounts that exceed $50 million.
In addition, we have agreed to compensate Athena for consulting fees of $15,000 per month beginning September 1, 2006 and ending August 31, 2007 and $5,000 per month for the five months thereafter. In addition to billings on a time and expense basis, this compensation shall include a success fee equal to a percentage of any transaction value.
I'm sure everybody on the inside is very interested in their share of a "Dnaprint Pharmaceutical" spin-off/stock dividend to common holders/reverse split to common. That's certainly where the value is going to be. Do you think that scenario is plausible? TIA
frog, do you think the FDA "black boxing" EPO drugs could directly affect DnaPrint? TIA
mlb, they just need the FDA to grant the AIM patents and make this method mandatory.
Methods: Pan genome maps of Ancestry Informative Markers to estimate individual biogeographical ancestry admixture for patient samples, integrated with a case/control design were used to screen the genome.
Sounds more like the basis for a class action suit.
Sam, you should keep this in mind:
Sale of Biofrontera Shares
On October 30, 2006, Biofrontera, AG registered its stock on the Düsseldorf and Frankfurt, Germany stock exchanges. This has enabled us to sell 32,000 and 50,000 shares of Biofrontera stock during the end of December 2006 and early January 2007, for proceeds of $554,638 and $644,000, respectively, of which approximately $661,000 was used to pay debt, and the remaining amount was used to fund operations. During February 2007, we reached an agreement to sell the remaining shares of Biofrontera stock for a total of 4.4 million Euros or approximately $5.9 million USD. We will receive 500,000 Euros per month from February 2007 through September 2007 and then the remaining balance in October 2007. Approximately 40% of these proceeds are required to be used to pay on the Dutchess debt.
LIQUIDITY AND CAPITAL RESOURCES
General
During 2006, our operating requirements generated negative cash flow from operations as we continued to engage in testing and development of our products. Our cash used by operating activities during 2006 was $5,781,789. We also had principal payments on capital lease obligations of approximately $197,000 and purchases of laboratory equipment and computers of approximately $391,000. The resulting cash shortfall was financed primarily through proceeds from notes payable of $4,539,024, net of costs and proceeds of approximately $555,000 from sale of Biofrontera shares. We also borrowed $50,000 on our line of credit and received a short-term loan of $126,880 which was paid back during 2006. The repayment of notes of $3,018,851 was financed by the Dutchess puts which resulted in proceeds from common stock of $3,033,802, net of stock issuance costs.
Frog, this statement is just wrong:
You can hardly bring a civil case against a bankrupt entity...unless you just want to make a statement of principle.
retro, I'm not a lawyer, or an accountant...but I would think that one of the 3... Harvard agreement, KBI-Biopharma, Default on the Dutchess notes...was a "change" that would be considered material and definitive. I e-mailed Dnaprint asking why 8k's were not filed...no response as of yet.
retro, the Dutchess agreement is fully backed by the assets of the company. What is to stop Dutchess from shorting the stock, driving the price down, accumulating shares, holding the company in default on the notes, demanding the 2 million or so in damages (which the company doesn't have, 40% of the sale of the Bio stock is to pay "OLD NOTES"...effectively, bankrupting the company and taking control? All of the preffered has been converted to common. Has Dutchess done this before? TIA
The Dutchess Investment agreement expires in May 2007, and we are working with Dutchess on putting another agreement with them in place.
We are in default of each of the Dutchess Notes due to not making the minimum principal payments. Dutchess has the right to charge us liquidated damages of up to 30% of the face amount of these notes. Dutchess has not exercised this right at December 31, 2006 nor at the time this report was issued. At December 31, 2006, we recorded a default penalty accrual in the amount of $2,143,500 for these potential liquidated damages. This is an estimate based upon the maximum amount that Dutchess could charge us and this estimate may change with time.
retro, I was only off by $600k. lol
retro,
WE MAY NOT HAVE SUFFICIENT SHARES AVAILABLE TO FULLY ACCESS THE EQUITY LINE WITH DUTCHESS AND MAY NEED TO SEEK ADDITIONAL CAPITAL TO MEET OUR WORKING CAPITAL NEEDS.
We may only issue a put to Dutchess if we have registered the shares of common stock. We have registered 962,500,000 shares that we may issue pursuant to the equity line and as of February 15, 2007 we have already issued 291,438,008 shares pursuant to prior registration statements. We have assumed that we will not issue more than the 962,500,000 shares we already registered pursuant to the exercise of our put right under the Investment Agreement, although the number of shares that we will actually issue pursuant to that put right may be more than or less than 962,500,000 shares depending on the trading price of our common stock. On February 15, 2007, the closing price of our common stock was $0.016. Assuming we issue puts only at $0.016, we would be able to access approximately $10.7 million of our equity line pursuant to the Investment Agreement based upon the shares we have registered and are unissued. We currently have no intent to exercise the put right in a manner that would require us to register more shares than the 962,500,000 shares we have registered, but if we were to exercise the put right in that manner, we would be required to file a subsequent registration statement with the Securities and Exchange Commission and for that registration statement to be deemed effective prior to the issuance of any such additional shares.
State the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date. As of February 15, 2007: 492,844,374.
already issued convertible notes, warrants, options...359,390,415
total 1.5 billion authorized
retro, at .016/share they can generate about 10.1 million.
absolutely, still holding...eom
not too smart....are'ya' boy...
Jever, the facts scare you?
I expect that too, flip. I recognized that 7 years ago. I have to ask what the "value" of my investment is. That would be 1.5 million out of a Billion.
Funding, licensing, revenue is URGENTLY needed.
We currently have a total of three SNPstream machines enabling us to offer testing services that can validate markers at high volumes, which is especially useful in the later stages of drug and diagnostics development during large clinical trials.
Disgusting...you do the math...we'll be LUCKY to get a reverse/split and stock dividend with a spin-off of dnaprint pharmaceuticals. LUCKY...
State the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date. As of February 15, 2007: 492,844,374. ]/b]
convertible notes, warrants, options...359,390,415
Still exercising puts:
Dutchess Put Notices
From January 1 to March 8, 2007, we exercised put notices in accordance with our agreement with Dutchess and received $554,762 of cash proceeds for which we issued 42,203,331 shares of our common stock to Dutchess. We used $470,590 of these proceeds as principal payments on our note payable with Dutchess.
Here's Tony still soaking us for 8%:
NOTE G - NOTES PAYABLE TO RELATED PARTIES
At December 31, 2006, our notes payable to related party is $257,147 owed to our Chief Scientific Officer. The annual interest rate is 8% and is accrued throughout the loan term. At December 31, 2006, we entered into a new note with him whereby the accrued interest of $19,066 was included in the principal of the note. Interest during 2007 will accrue at 8%, and the accrued interest and note is due in a lump sum payment on December 31, 2007. During 2006 this note was reduced by $300 for payments made on his behalf to third parties.
Dutchess Security Agreement
All of the Dutchess notes are secured by a security interest in substantially all of our assets.
yuk...
The Dutchess Investment agreement expires in May 2007, and we are working with Dutchess on putting another agreement with them in place
We anticipate that the funding we expect to receive from the put notices to Dutchess, the Dutchess notes which are paid with the puts, the sale of the equity investments available-for-sale and the minimum conversions of the outstanding debenture into common stock and the related exercise of the non-detachable warrants will fund our operating activities through 2007. However, the rate of progression on the research and development will depend on our ability to raise additional capital.
The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note B, the Company incurred a net loss of $12,348,364 during the year ended December 31, 2006 and has an accumulated deficit of $38,102,527 from inception to December 31, 2006. In addition, the Company is in default of its notes payable with Dutchess and is delinquent on lease payments, certain payments with research and development agreements and certain payables. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note B. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
We will receive 500,000 Euros per month from February 2007 through September 2007 and then the remaining balance in October 2007. Approximately 40% of these proceeds are required to be used to pay on the Dutchess debt.
root, that was is response to stocks'...calm, cool, and "collective". If you have to explain a joke, it's just not funny anymore.
for all intensive purposes...
Genotyping sales were generated primarily through work with universities with three customers being our major clients of these services during 2006. The increase of genotyping services of approximately $590,000 during 2006 compared 2005 was the result of the revenue from our acquisition of Ellipsis during late 2005. Three of our customers accounted for approximately $647,000 of our genotyping sales during 2006.
onco, I don't think it's coincidence that we stopped funding PT-401, and the FDA is "black boxing" EPO drugs. Too much of a "good thing" is killing poeple. Theranostics is the answer. Until Guidance is established, further research could be in vain. JMHO
stock, how does that equate to revenue? TIA
Nature, bounce off 200SMA. eom
In fact an 8k should have been filed.eom